Chronic Fatigue Syndrome and Viral Infections by Frédéric Morinet & Emmanuelle Corruble
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
1 
Chronic Fatigue Syndrome and Viral Infections 
Frédéric Morinet1,* and Emmanuelle Corruble2 
1Hospital Saint-Louis,  
Center of Innovative Therapy in Oncology and Hematology (CITOH),Paris,  
2Paris XI University, INSERM U 669, Department of Psychiatry,  
Bicêtre University Hospital, Assistance Publique–Hôpitaux de Paris, 
 France 
1. Introduction  
The dream of all clinicians and researchers is to give their name to an illness, whatever the 
technique used to make the discovery. During the 20th century and the early part of the 21st 
century, several viruses have been identified by different procedures. Using electron 
microscopy, Epstein and Barr (Epstein et al., 1965) detected a Herpes virus in the lymphoid 
cells of a native African boy with a jaw tumor identified by the surgeon, Denis Burkitt 
(Burkitt, 1962). A few years later, using electrosyneresis, Blumberg detected the Hepatitis B 
antigen in the blood of an Australian aborigine (Blumberg et al., 1967, 1965). This 
immunological procedure was also used in 1975 by Yvonne Cossart to detect human 
parvovirus B19 in the serum of a blood donor in London (Cossart et al., 1975).  
In the last decade, molecular biology techniques have prevailed for identifying new viruses. The 
viruses of Hepatitis C (Choo et al., 1989), Kaposi sarcoma (Chang et al., 1994) and Merkel 
carcinoma (Feng et al., 2008) have been detected in blood samples and skin biopsies. After 
detection, polymerase chain reaction (PCR) has been used routinely to identify pathogens. PCR 
is a specific and highly sensitive procedure. Its sensitivity explains the false positive results due 
to DNA contamination and great caution is required when positive PCR results are obtained.  
There are several reasons why viral infections have long been suspected to be the cause of 
Chronic Fatigue Syndrome (CFS). Most patients report that their symptoms started 
suddenly with a flu-like illness. It is also known that some viruses, especially polio (an 
enterovirus), can produce a syndrome of permanent post-infection fatigue. Many people 
with CFS also have unusual immunological activity which might result from viral infections 
or predispose them to such infections. Nevertheless, at present the role of viruses in CFS 
remains unresolved, as it is for many autoimmune diseases such as type I diabetes and 
multiple sclerosis. If their precise etiological role remains elusive, despite their in vivo 
persistence, it seems that viruses may trigger the disease and then vanish. This mechanism, 
termed “hit and run”, was described initially in bovine papillomatosis. Bovine 
papillomavirus is detected only at the initial stage of infection and never at the neoplastic 
stage (Favre, personal communication). Consequently, it may be that when a clinical 
diagnosis of CFS is made, it is too late to detect any possibly causative virus. 
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Finally, finding a viral etiology for CFS would open the door to specific therapy that would 
bring hope to patients. 
After presenting a summary of CFS, we shall describe viral candidates and try, with the help 
of examples, to explore some possible mechanisms of virus infection. 
2. Background  
Interest in CFS increased in the early 1980s after an epidemic of neurological symptoms, 
referred to as "myalgic encephalomyelitis" (ME), occurred among the staff of a London 
hospital. Nowadays, CFS refers to the range of complaints found in ME, or chronic fatigue 
and immune dysfunction syndrome (Prins et al., 2006). CFS is characterized by persistent 
and unexplained fatigue, resulting in severe impairment of daily functioning. 
2.1 Definition of CFS 
The most widely supported scientific definition of CFS, which is now considered the 
standard, is that made in 1994 by the US Center for Disease Control and Prevention (Fukuda 
et al., 1994). In this definition, the illness is identified by the presence of subjective 
symptoms, disability and absence of other explanatory illnesses, and not by objective 
validators, such as physical signs or abnormalities detectable by laboratory tests or imaging 
techniques (Prins et al., 2006).  
Criteria of CFS are the following: 
- Persistent or relapsing unexplained chronic fatigue 
- Fatigue lasting for at least 6 months  
- Fatigue of new or definite onset  
- Fatigue not resulting from an organic disease or from continuing exertion  
- Fatigue not alleviated by rest  
- Fatigue resulting in a substantial reduction in previous occupational, educational, social 
and personal activities  
- Four or more of the following symptoms, concurrently present for 6 months: impaired 
memory or concentration, sore throat, tender cervical or axillary lymph nodes, muscle 
pain, pain in several joints, new headaches, non-refreshing sleep, or malaise after 
exertion 
Are excluded: 
- Medical condition explaining fatigue  
- Major depressive disorder (psychotic features) or bipolar disorder  
- Schizophrenia, dementia or delusional disorder  
- Anorexia nervosa, bulimia nervosa  
- Alcohol or substance abuse  
- Severe obesity. 
2.2 Epidemiology and clinical signs 
The prevalence of CFS among adults ranges from 0.25% to 0.5%, with higher rates in women 
(75%) than men (25%), and more frequent in people of lower educational attainment and 
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occupational status. The estimated prevalence is lower among children and adolescents than 
in adults.  
CFS begins generally in young adults. The main complaint is of a persistent, severe fatigue, 
frequently associated with pain (mainly myalgia and headache), cognitive dysfunction, 
and/or gastrointestinal problems. These symptoms result in substantial reduction in 
occupational, educational, social, and personal activities. A thorough history, a meticulous 
physical and mental status examination and a range of laboratory tests and an assessment of 
fatigue severity and functional impairment are needed to diagnose CFS. 
Initially, CFS was compared with neurasthenia (Afari et al., 2003). Psychiatric comorbidities, 
especially depressive disorders, are commonly found (Afari et al., 2003; Choa et al., 2006).  
Full recovery from CFS without treatment is rare. Poorer outcomes are predicted with 
psychiatric comorbidities and a better outcome may be predicted where there is a lower 
baseline fatigue (Prins et al., 2006). 
2.3 Etiology 
The potential roles of many somatic and psychosocial factors in the etiology of CFS have 
been explored (Prins et al., 2006), including: viral infections, immune dysfunction, 
neuroendocrine disorders, central nervous system dysfunction, muscle structure, exercise 
capacity, sleep patterns, genetics, personality, and neuropsychological processes. Both 
etiology and pathogenesis are probably multifactorial. To explain this complex disorder, 
interactions between predisposing, precipitating and perpetuating factors have been 
proposed. 
Among predisposing factors, personality (neuroticism and introversion), lifestyle and 
genetics have been suggested. Among precipitating factors that might trigger the onset of 
CSF, acute physical stress, such as infection (flu-like illness, infectious mononucleosis, Q 
fever and Lyme disease), serious injuries, surgery, pregnancy, labor and psychological stress 
such as major life events have been cited.  
3. DNA viruses   
3.1 Herpes virus 
The Herpes virus family includes DNA lymphotropic and  neurotropic viruses. Epstein-Barr 
virus (EBV), Kaposi sarcoma virus (HHV-8) and cytomegalovirus (CMV) are lymphotropic 
whereas Herpes simplex virus (HSV), Varicella-zoster virus (VZV) and human Herpes virus 
6 (HHV-6) are neurotropic. After an acute infection, these viruses persist in vivo and may 
reactivate during immunosuppression or after a stress. All, except EBV and HHV-8 are 
accessible to antiviral agents. For EBV and HHV- 8, reduction of immunosuppression seems 
to be sufficient. 
3.1.1 Herpes virus and disease 
There are two types of Herpes simplex virus: type 1 causes oral lesions whereas type 2 
causes genital lesions. The skin lesions are typically vesicular. With the type 2 virus, the 
main problem is that if genital lesions occur during pregnancy, there is a risk of 
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transmission to the neonate at delivery. With the type 1 virus, there is a risk of encephalitis, 
but this is very rare and depends on the patient’s genetic background. Herpes simplex 
encephalitis is due to a series of monogenic primary immunodeficiencies that impair TLR3 
and UNC-93B-dependent production of INF-alpha/beta and Interferon lambda in the 
central nervous system, at least in a small number of children (Sancho-Shimizu et al., 2007). 
Consequently, it would seem that treatment of Herpes simplex encephalitis with INF-alpha, 
as well as with acyclovir, could improve prognosis. Encephalitis may also occur during 
infection by HHV-6, principally in immunocompromised patients. With lymphotropic 
viruses, the clinical signs are essentially seen in immunodeficient patients, such as organ 
transplant and bone marrow recipients and HIV patients. EBV induces lymphoma, HHV-8 
is the viral agent of Kaposi sarcoma and lymphoma, and CMV is the agent of interstitial 
pneumonia and retinitis. 
3.1.2 Herpes virus and CFS 
Herpes virus is a popular hypothetical candidate for the pathogenesis of CFS, either by 
primary infection or after the reactivation of a latent infection. Two Herpes viruses, EBV and 
HHV-6, are suspected of playing a role in the development of CFS. 
Prospective cohort studies have suggested that acute EBV infection triggers a post-infective 
syndrome in approximately 10% of patients, when evaluated 6 months after onset. 
Nevertheless, in a pilot study, serological patterns of anti-EBV antibody in the patients with 
CFS were not different from those who recovered promptly (Cameron et al., 2010). In 
addition, the levels of circulating EBV DNA were within the range found in healthy blood 
donors. Finally, in a double-blind, placebo-controlled study, acyclovir therapy in patients 
with CFS and persistent EBV antibodies did not improve CFS (Strauss et al., 1988). These 
findings must, however, be interpreted carefully since using acyclovir to treat EBV infection 
is questionable (personal data). In another study, valgancyclovir, an oral pro-drug of 
ganciclovir, was used to treat CFS patients with high EBV antibody titers (Kogelnik et al., 
2006; Lerner et al., 2001). Clinical improvement was observed with a decrease in EBV 
antibody titer. These findings must be confirmed, but we cannot exclude the possibility that 
the drug has an immunomodulatory effect. Indeed, like acyclovir, valgancyclovir is not an 
ideal drug to treat EBV reactivation. 
Because HHV-6 causes a life-long, ineradicable infection, and because of its broad tissue 
tropism, it has been reasonable to speculate that it might be a trigger and perpetuating factor 
for CFS (Komaroff, 2006). The similarities between CFS and several neurological diseases 
associated with HHV-6 have reinforced this speculation. In post-transplant patients, HHV-6 
in the CNS causes cognitive dysfunction and fatigue similar to that reported by CFS 
patients. Human HHV-6 isolates are classified into two variants, termed HHV-6A 
(neurotropic) and HHV-6B, on the basis of their distinct genetic, antigenic and biological 
characteristics, but the specific pathogenicity of each variant remains poorly understood. 
Yalcin detected equal frequencies of HHV-6A and HHV-6B in 13 patients with CFS (Yalcin 
et al., 1994).  
Clinical  studies with antiviral drugs that have in vitro activity  against HHV-6 (for example 
foscarnet) could  provide strong evidence for, or against, any link between HHV-6 infection 
and development of CFS. 
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3.2 Parvovirus  
Autonomous parvoviruses, known to infect man, comprise parvovirus B19 and the recently 
discovered PARV4 and human bocavirus. PARV4 was originally detected in plasma from a 
patient with an "acute infection syndrome” resembling that of primary human 
immunodeficiency virus (HIV) infection. PARV4 is known to be widespread, specifically in 
people with a history of parenteral exposure (injecting drug users, hemophiliacs, 
polytransfused patients), with a strikingly higher incidence amongst those infected with 
HIV. Human bocavirus was originally found in the respiratory tracts of young children. 
Although it is frequently detected by PCR in the nasopharynx of viremic patients with 
primary lower respiratory tract infections, other co-infecting respiratory viruses are 
frequently detected (Servant et al., 2010). As far we know, only parvovirus B19 is involved in 
CFS. 
3.2.1 Parvovirus B19 and disease  
Discovered in 1975 (Cossart et al.,1975), B19  can cause  a wide  range of mild and self-
limiting clinical signs, such as erythema infectiosum (fifth disease) and oligoarthritis (Servant 
et al., 2010). B19V infection may also cause acute anemia due to aplastic crisis in patients 
with shortened red cell survival and the chronic anemia of immunocompromised patients, 
i.e. HIV patients and those with congenital immunodeficiency, undergoing chemotherapy 
for malignancies or after organ transplant. It may also result in hydrops fetalis or fetal death. 
Erythroid progenitor cells are specifically targeted through expression of globoside P 
antigen, which acts as the receptor for B19 virus, explaining the development of anemia. 
Recently, cases of neurological signs and myocardial infections have been associated with 
B19 infection and the spectrum of B19-linked diseases may increase further. The primary 
route of B19V transmission is the respiratory tract (via aerosols), with a majority of 
infections occurring during childhood. The infection may also be transmitted by organ 
transplant and especially by transfusion of blood components, in particular packed red cells 
from blood collected during the short pre-seroconversion viremic phase. In classical natural 
history, an acute B19V infection occurring in immunologically competent individuals is 
controlled by neutralizing antibodies. A transient, high level viremia lasts for less than one 
week and declines with the appearance of specific IgM antibodies, which persist for eight to 
ten weeks, followed by the appearance of life-long specific IgG antibodies. Persistent 
infection may be observed in immunocompromised patients unable to produce neutralizing 
antibodies able to clear the virus, leading to chronic B19V carriage with or without anemia. 
In this case, an infusion of immunoglobulins is necessary. However, even if the immune 
response of healthy subjects is able to clear infection and provide life-long protection against 
B19V, persistence of infection has been reported in the bone marrow of immunocompetent 
subjects with or without symptoms, and recently persisting low levels of B19V DNA were 
found in the blood of some immunocompetent subjects several years after primary infection. 
The mechanism of such chronic B19V carriage remains unclear.   
3.2.2 Parvovirus B19 and CFS 
McGhee (McGhee et al., 2005) reported the case of a 16-year-old boy with no evidence of 
immunodeficiency who had a 2-year history of chronic fatigue, low-grade fever and 
slapped-cheek rash associated with a chronic parvovirus B19 viremia that was detected by 
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quantitative PCR. Parvovirus B19 titers for IgG and IgM were strongly positive. Three 
months of high dose (total 560 g) intravenous immunoglobulin (IVIG) was required before 
both symptoms and viremia resolved. Slapped-check rash is not included in the diagnostic 
criteria of CFS, so in this case we must speak of chronic fatigue rather than CFS. It is not 
known whether his improvement and that of other patients described in the literature by 
Kerr et al. results from increased titers of specific antibody or is due to the 
immunomodulatory effects of high dose IVIG (Kerr et al., 2003). Whatever the mechanism, it 
seems that IVIG is a promising treatment for the chronic fatigue following Parvovirus B19 
infection. Kerr (Denavur & Kerr, 2006) claimed that acute symptomatic parvovirus B19 
infection is associated with elevated circulating TNF-alpha and IFN-gamma and may be 
followed by CFS. Nevertheless Barbara Cameron, by analyzing serum cytokine levels in 
post-infective fatigue syndrome patients and in healthy controls, found no statistically 
significant differences in serum levels of any cytokines at any time (Cameron et al., 2010).  
3.3 Other DNA viruses 
Two other DNA viruses have been unsuccessfully associated to CFS. Firstly, the human 
polyomavirus JC which causes progressive multifocal leukoencephalopathy, and which 
infects granule cell neurons in the cerebellum and sometimes infects grey matter. It may also 
cause meningitis (Tan & Koralnik, 2010). JC virus-induced disorders are essentially observed 
in immunosuppressed patients, whether or not HIV positive. There is no specific antiviral 
drug against the JC virus and the goal of current treatment is to restore the host’s adaptive 
immune response to the JC virus so as to control infection. At present, there is no proof that 
JC virus induces CFS. The second virus putatively associated with CFS is a circovirus, the 
TTvirus. Circoviruses have a questionable pathogenicity in man, but in animals they may 
infect the brain and cause disease, e.g., post-weaning multisystemic wasting syndrome of 
pigs (Hino, 2002). Only one report suggests that TTvirus may induce CFS (Grinde, 2008). 
Further studies are necessary to implicate TTvirus, a non-pathogenic virus, in this 
syndrome.   
4. RNA viruses  
4.1 Enterovirus 
Infection by enterovirus in man, although often asymptomatic, is responsible for a wide 
range of acute diseases (Morinet, 2008). In addition, they are possibly involved in the 
genesis of chronic enterovirus diseases, including chronic myocardial diseases, post-
poliomyelitis syndrome and even juvenile-onset (type1) diabetes mellitus (see below). The 
role of enteroviruses in the pathogenesis of CFS, an old saga, has been largely disputed The 
detection, over a long period of time, of enterovirus structural proteins (VP-1 in sera) and 
enterovirus RNA in the muscle biopsy specimens of patients with CFS is disturbing 
(Douche-Aourik, 2003). Gow (Gow et al., 1994) investigated a large number of muscle 
biopsies from patients with either CFS or neuromuscular disorders and demonstrated the 
presence of enteroviral RNA by RT-PCR in 26.4% and 19.8% of samples respectively. It is 
necessary to demonstrate enterovirus within the muscle fibres by in situ PCR to prove that 
viral persistence alters the metabolism of the cells and thus show that such abnormalities 
cause clinical symptoms (Dalakas, 2003). 
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4.2 Other RNA viruses  
A case report recently described an adolescent boy who was diagnosed as suffering from 
CFS five months after infection with H1N1 influenza (Vallings, 2010). Laboratory test results 
were normal. Other articles investigated the role of GB virus in CFS (Jones et al., 2005; 
Sullivan et al., 2011). GB virus, a flavivirus, has many properties that require study to assess 
its possible association with CFS; effectively this virus replicates preferentially in peripheral 
blood mononuclear cells, primarily B and T lymphocytes, and in bone marrow in vivo. 
Nevertheless, two of twelve CFS patients and one of 21 healthy controls were seropositive 
for GB virus; consequently there is no evidence this virus is associated with CFS.  
Among RNA viruses, there have been conflicting findings with the neurotropic, negative-
stranded RNA Borna virus (De la Torre, 2002). This virus is the causative agent of Borna 
disease, a sporadic and often fatal neurological disease of horses and sheep in central 
Europe and which has been known since the 18th century (Schwemmle, 2001). The mode of 
transmission is unknown but is thought to be by saliva, or nasal and conjunctival secretions. 
Serological and molecular epidemiological studies suggest that such a virus can infect man 
(Nowotny & Kolodziejek, 2000). Despite enormous efforts from many laboratories, it is still 
unclear whether Borna virus infection is associated with human psychiatric disease and 
CFS. Inadvertent sample contamination has been suggested (Durrwald et al., 2007; 
Schwemmle 2001; Evengard et al., 1999). 
Finally, two studies have reported that most CFS patients harbour a gamma retrovirus, the 
xenotropic murine leukemia-related virus (XMRV) in blood (Kearney & Maldarelli, 2010; 
Lombardi et al., 2009). This finding has raised speculation that it may cause the syndrome. 
However, four other laboratories could not replicate this finding, whilst four new studies 
found it only as a laboratory contaminant (Calaway, 2011; Cohen, 2011; Kaiser, 2011; 
Schutzer et al., 2011; Shin et al., 2011; Kean, 2010; Mayor, 2010; Sato et al., 2010; Stoye et 
al.,2010; Coffin & Stoye, 2009). In 2011, at a retrovirology meeting in Boston, Massachusetts, 
researchers presented evidence that this retrovirus is, in effect, a laboratory artefact and not 
a human pathogen. 
5. Viral persistence 
A virus must have two essential characteristics in order to persist in a host (De la Torre et al., 
1991). Firstly, the virus, by any one of several means, must escape the host’s immunological 
surveillance. One classical mechanism is virus-induced down-regulation of HLA class I. The 
infected cell becomes invisible to TCD8+ cytotoxic lymphocytes. This mechanism is used 
extensively by Herpes viruses. The Herpes virus group is unique in that virtually all people 
have latent infections in their peripheral ganglia and/or their white blood cells, which may 
be reactivated to cause symptomatic disease, even decades after initial infection. One such 
virus, the Varicella Zoster Virus, induces shingles (zoster) many years after varicella 
infection in infancy. Virtually all the symptoms of shingles occur also in CFS, except for the 
painful rash (Shapiro, 2009). Secondly, the virus must generate defective particles and 
variants that diminish the expression of its gene product. For example the measles virus, 
after a primary infection, causes systemic disease with a typical skin rash. But during its 
replication it produces defective particles which persist in the CNS where their 
accumulation may lead to subacute sclerosing panencephalitis after ten years. This disease is 
prevented by measles vaccination. 
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Another mechanism by which persistent virus infection produced disease was uncovered 
after the discovery that some viruses could alter cell differentiation (i.e. the “luxury“ 
function of cells), without causing cell destruction, and thereby altering homeostasis. For 
example, whilst examining the effects of persistent lymphocytic choriomeningitis virus (an 
RNA virus which infects mice) infection on differentiated neuroblastoma cells, Oldstone 
(Oldstone et al., 1982) noted abnormalities in the synthesis and degradation of the 
neurotransmitter acetylcholine caused by decreased production of the appropriate acetylase 
or esterase enzyme. Nevertheless, these neuroblastoma cells were of normal morphology, 
growth rate, cloning efficiency and in levels of total RNA, DNA, protein and vital enzyme 
synthesis. Infected cells were indistinguishable from infected ones by both light and high 
resolution electromicroscopy. In man, after infection with influenza virus, peripheral blood 
lymphocytes no longer performed their expected specialized functions, including antibody 
synthesis and they no longer had the capacity to act as killer cells (Oldstone, 2002).  Hence, 
this human RNA virus altered the different cell functions without lysing or destroying them. 
Viruses act very subtly on a cell and disorder its function, but not so severely as to kill the 
infected cell. Yet, for the host, the end result is perturbed homeostasis and disease.   
Persistent enterovirus infections have been implicated in a number of chronic human 
diseases including dilated cardiomyopathy, chronic muscle disorders, type I diabetes 
mellitus and myalgia encephalomyelitis/CFS. Chia (Chia et al., 2010) demonstrated the 
presence of enterovirus protein, viral RNA and the replication of non-cytopathic viruses 
from stomach biopsies from CFS patients, years after the initial acute flu-like illness. More 
interestingly, in a prospective, longitudinal study of three patients, all developed acute 
enterovirus infections, documented by the presence of enteroviral RNA in the secretions, 
blood or affected tissues, and, over the next few years, this was followed by a range of 
symptoms consistent with CFS. Years after acute infections with respiratory/gastrointestinal 
symptoms, viral protein and RNA were found in stomach biopsies. Chronic infections in 
immunocompetent hosts may represent stalemate between attenuated, intracellular viruses 
and an ineffective immune response. 
6. Hit and run 
Over the past twenty years, no study has found conclusive evidence of an infectious etiological 
agent for CFS. The disorder is complex and multifactorial; nevertheless we cannot exclude the 
possibility that some infectious agent may trigger the disorder and then vanish. This 
mechanism, termed “hit and run” is well known in virology. In vitro, B cell cancers tend to 
maintain gammaherpesvirus genomes, whereas Kaposi’s sarcoma and nasopharyngeal 
carcinoma tend to lose them (Stevenson et al., 2010). In bovine papillomatosis, at the stage of in 
situ carcinoma, viral sequences are no longer detected. It also seems that the HTLV-1 Tax 
protein is absent at the final step of leukemia/lymphoma. Outside the field of oncology, 
paramyxovirus and respiratory viruses exhibit a “hit and run” phenomenon indicated by the 
development of asthmatic symptoms long after the infection has cleared (Holtzman et al., 
2004). A single paramyxoviral infection of mice (C57BL6/J strain) not only produces acute 
bronchiolitis but also triggers a chronic response with airway hyper-reactivity and goblet cell 
hyperplasia lasting for at least a year after complete viral clearance (Walter et al., 2002). A “hit 
and run” event may also occur where antibodies to a virus recognize similar amino-acid 
sequences or patterns found in host cells. This cross-reactivity is termed molecular mimicry 
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and does not require a replicating agent, and an immune mediated injury may occur after the 
immunogen has been removed (Oldstone, 1998). 
7. Conclusion 
CFS is a common problem and all clues as to its possible cause are welcome. Despite intense 
efforts, no virus has been clearly incriminated. Their detection seems more casual that 
causal. In addition, the study of viral infections in monozygotic twins who are discordant 
for CFS does not suggest that a virus is the culprit (Koelle et al., 2002). The recent association 
of XMRV with CFS re-opens the debate about laboratory contamination; whether the 
detection of this gammaretrovirus indicates a real infection or whether it is due to a 
laboratory artefact remains highly controversial. If the findings linking XMRV with CFS are 
not due to laboratory artefacts, how can we explain the failure of other investigators to 
replicate the findings? Different inclusion criteria for CFS cannot account for the difference 
between 0% and 67% found in the laboratories (Weiss, 2010).  
One over-arching question is the following: is CFS an infectious disease? If this is the case, 
despite the absence of supporting data, patients with CFS must abstain from blood 
donation, as has been suggested by Bridget M. Kuehn (Kuehn, 2010) in a provocative 
editorial of the JAMA. At present, there has been no confirmation that transfusion is 
associated with the disease.  
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